Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

>.  

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 According to Jeff Howell, Partner ... ITRA Global, new development in Downtown Toronto is expanding ... approving another 755 storeys of new development last week ... will be dominating the Toronto skyline for the foreseeable ... unquenchable thirst for new development. , As the Toronto ...
(Date:9/16/2014)... September 16, 2014 RENU 28, the world's ... became available for purchase in Australia and New Zealand ... tour beginning September 16th. The tour will make stops in ... Bundaberg on the 18th, Sydney on the 20th, and Melbourne ... Australia and New Zealand and to educate people about the ...
(Date:9/15/2014)... UPTON, NYHeat drives classical phase transitionsthink solid, ... happen when the temperature drops. If phase ... where quantum mechanics reigns, subtle fluctuations can ... from the U.S. Department of Energy,s Brookhaven ... explored this frigid landscape of absolute zero ...
(Date:9/15/2014)... 2014   Global Science & Technology, Inc. ... and services for satellite and weather systems, was ... Services (OASIS) from the General Services Administration (GSA) ... provide the government best-value solutions for complex professional ... in Pool 4. The OASIS SB award has ...
Breaking Biology Technology:ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Global Wellness Company Hosts ASEA Australia Tour September 16-22 2Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3
... EDMONTON, Sept. 30 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. ... company developing and commercializing products for the treatment ... a pipeline of late-stage immunotherapy product candidates from ... of product candidates consists of five monoclonal antibodies ...
... ... , ... (PRWEB) September 30, 2009 -- Authenware , a leading keystroke biometric developer, today ... with software-based biometric protection for its federal employees. Calculating intrinsic behavioral typing patterns ...
... Inc. (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime, ... and webcast on Wednesday, October 28, at 5:00 p.m. ET ... U.S. / Canada Dial-in Number: 800.299.6183, ... Participant Code: 51404008, Replay Dial-in Number: 888.286.8010, ...
Cached Biology Technology:Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline 2Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline 3Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline 4Spain's Health Ministry Contracts Authenware to Fortify System Security Prior to Flu Season 2Spain's Health Ministry Contracts Authenware to Fortify System Security Prior to Flu Season 3BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET 2
(Date:9/15/2014)... disease (CVD) claims 17 million lives each year, while ... million. 1 New research presented by international scientists ... France on September 15, 2014, suggests that milk consumption ... At the Milk and Dairy Products in Human ... for hypertension and CVD was examined by Dr. Sabita ...
(Date:9/15/2014)... need for vitamin E and how much is enough, ... of this essential micronutrient are especially critical for the ... may become pregnant. , A lifelong proper intake of ... complicated by the fact that this nutrient is one ... It has been estimated that only a tiny fraction ...
(Date:9/12/2014)... , September 12, 2014 ... ( http://www.researchandmarkets.com/research/trs4c7/global ) has announced the addition ... Report 2014" report to their offering. ... Industry Report 2014 is a professional and ... the global fingerprint lock industry. , ,The ...
Breaking Biology News(10 mins):Dairy consumption linked to lower blood pressure and cardiovascular disease risk 2Vitamin E intake critical during 'the first 1,000 days' 2Vitamin E intake critical during 'the first 1,000 days' 3Global Fingerprint Lock Industry Report 2014 2
... compound found in cocoa, are so striking that it may ... health, reports Marina Murphy in Chemistry & Industry, the magazine ... Medical School, told C&I that epicatechin is so important that ... spent years studying the benefits of cocoa drinking on the ...
... joint funding from the Engineering and Physical Science Research ... develop an innovative sensor to detect bacteria. The new ... fluorescent signal when it encounters bacteria, allowing scientists to ... methodologies. , The new technology will be ...
... childbearing age struggle with the heartache of infertility. Now there ... of a mutation in a gene that causes male infertility ... dominant mutation that leads specifically to infertility in a mammal ... for similar mutations in the DNA of infertile men. , ...
Cached Biology News:Cocoa 'vitamin' health benefits could outshine penicillin 2Researchers find gene mutation that causes infertility in male mice 2
Phospho-TAO2 (S181) Affinity Purified Polyclonal Ab Protein Family: Other Intracellular Kinases...
PEG 8000, Molecular Biology Grade...
... Deacetylase (HDAC) Antibody Sampler Kit Kit ... Catalog #2062, 40 ul Histone Deacetylase 3 ... Deacetylase 4 (HDAC4) Antibody, Catalog #2072, 40 ... #2082, 40 ul Histone Deacetylase 6 (HDAC6) ...
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: